BNP Paribas Financial Markets Has $531,000 Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

BNP Paribas Financial Markets raised its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 15.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,946 shares of the biopharmaceutical company’s stock after acquiring an additional 1,570 shares during the period. BNP Paribas Financial Markets’ holdings in Agios Pharmaceuticals were worth $531,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. D. E. Shaw & Co. Inc. grew its holdings in shares of Agios Pharmaceuticals by 87.3% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock valued at $29,245,000 after purchasing an additional 316,100 shares during the last quarter. Seven Eight Capital LP acquired a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $1,693,000. Edgestream Partners L.P. bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth $1,814,000. Farallon Capital Management LLC increased its holdings in shares of Agios Pharmaceuticals by 1.1% during the second quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock worth $243,822,000 after buying an additional 63,900 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Agios Pharmaceuticals by 9.0% in the 2nd quarter. Federated Hermes Inc. now owns 13,394 shares of the biopharmaceutical company’s stock valued at $578,000 after acquiring an additional 1,108 shares during the last quarter.

Agios Pharmaceuticals Stock Up 2.1 %

Shares of Agios Pharmaceuticals stock opened at $38.97 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $20.96 and a 52 week high of $62.58. The business has a 50 day moving average price of $50.02 and a 200-day moving average price of $46.64. The company has a market cap of $2.22 billion, a PE ratio of 3.43 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Raymond James reiterated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $56.33.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.